Vadadustat: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== Vadadustat == | == Vadadustat == | ||
[[File:Vadadustat.svg|thumb|Chemical structure of Vadadustat]] | [[File:Vadadustat.svg|thumb|right|Chemical structure of Vadadustat]] | ||
'''Vadadustat''' is a pharmaceutical drug that acts as a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). It is primarily used in the treatment of anemia associated with chronic kidney disease (CKD). | '''Vadadustat''' is a pharmaceutical drug that acts as a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). It is primarily used in the treatment of anemia associated with chronic kidney disease (CKD). Vadadustat works by stabilizing the hypoxia-inducible factor (HIF), which leads to increased production of endogenous erythropoietin and improved iron metabolism, thereby stimulating erythropoiesis. | ||
== Mechanism of Action == | == Mechanism of Action == | ||
Vadadustat | Vadadustat inhibits the activity of prolyl hydroxylase enzymes, which are responsible for the degradation of hypoxia-inducible factor (HIF) under normal oxygen conditions. By inhibiting these enzymes, Vadadustat stabilizes HIF, allowing it to accumulate and activate the transcription of genes involved in erythropoiesis, iron metabolism, and oxygen homeostasis. This results in increased production of [[erythropoietin]], a hormone that stimulates the production of red blood cells in the bone marrow. | ||
== Clinical Use == | == Clinical Use == | ||
Vadadustat is | Vadadustat is indicated for the treatment of anemia due to chronic kidney disease in adult patients. Anemia is a common complication of CKD, often resulting from reduced erythropoietin production by the kidneys. By increasing endogenous erythropoietin levels, Vadadustat helps to alleviate anemia and reduce the need for exogenous erythropoietin-stimulating agents (ESAs). | ||
== | == Administration and Dosage == | ||
Vadadustat | Vadadustat is administered orally, and the dosage is typically adjusted based on the patient's hemoglobin levels and response to treatment. It is important to monitor hemoglobin levels regularly to avoid excessive erythropoiesis and potential complications such as [[hypertension]] or thromboembolic events. | ||
== Side Effects == | == Side Effects == | ||
Common side effects of Vadadustat include | Common side effects of Vadadustat include [[nausea]], [[diarrhea]], [[hypertension]], and [[headache]]. As with other treatments for anemia, there is a risk of cardiovascular events, and patients should be monitored for signs of [[thrombosis]] or [[hypertension]]. | ||
== Related Pages == | == Related Pages == | ||
| Line 27: | Line 27: | ||
* [[Erythropoietin]] | * [[Erythropoietin]] | ||
* [[Hypoxia-inducible factor]] | * [[Hypoxia-inducible factor]] | ||
[[Category:Pharmaceutical drugs]] | [[Category:Pharmaceutical drugs]] | ||
[[Category:Anemia treatments]] | [[Category:Anemia treatments]] | ||
[[Category: | [[Category:Chronic kidney disease]] | ||
Latest revision as of 04:02, 13 February 2025
Vadadustat[edit]
Vadadustat is a pharmaceutical drug that acts as a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). It is primarily used in the treatment of anemia associated with chronic kidney disease (CKD). Vadadustat works by stabilizing the hypoxia-inducible factor (HIF), which leads to increased production of endogenous erythropoietin and improved iron metabolism, thereby stimulating erythropoiesis.
Mechanism of Action[edit]
Vadadustat inhibits the activity of prolyl hydroxylase enzymes, which are responsible for the degradation of hypoxia-inducible factor (HIF) under normal oxygen conditions. By inhibiting these enzymes, Vadadustat stabilizes HIF, allowing it to accumulate and activate the transcription of genes involved in erythropoiesis, iron metabolism, and oxygen homeostasis. This results in increased production of erythropoietin, a hormone that stimulates the production of red blood cells in the bone marrow.
Clinical Use[edit]
Vadadustat is indicated for the treatment of anemia due to chronic kidney disease in adult patients. Anemia is a common complication of CKD, often resulting from reduced erythropoietin production by the kidneys. By increasing endogenous erythropoietin levels, Vadadustat helps to alleviate anemia and reduce the need for exogenous erythropoietin-stimulating agents (ESAs).
Administration and Dosage[edit]
Vadadustat is administered orally, and the dosage is typically adjusted based on the patient's hemoglobin levels and response to treatment. It is important to monitor hemoglobin levels regularly to avoid excessive erythropoiesis and potential complications such as hypertension or thromboembolic events.
Side Effects[edit]
Common side effects of Vadadustat include nausea, diarrhea, hypertension, and headache. As with other treatments for anemia, there is a risk of cardiovascular events, and patients should be monitored for signs of thrombosis or hypertension.
